WHO ICTRP trial
Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral…
JPRN-UMIN000011679 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-UMIN000011679 |
|---|---|
| Public title | Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancer |
| Scientific title | Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancer - CCOG1202 |
| Primary sponsor | Chubu Clinical Oncology Group |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | Unresectable metastatic or recurrent colorectal cancer |
| Interventions | XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 irinotecan 130mg/m2 day1 Capecitabin 1600mg/m2/day day1-15 |
| Registration date | Aug 9, 2013 |
| Target size | 25 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: